OTC:AKBLF ALK-Abelló A/S (AKBLF) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free AKBLF Stock Alerts $17.90 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$17.90▼$17.9050-Day Range$17.90▼$18.6552-Week Range$8.20▼$19.90VolumeN/AAverage Volume800 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesStock AnalysisAnalyst ForecastsChartHeadlines Get ALK-Abelló A/S alerts: Email Address Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About ALK-Abelló A/S Stock (OTC:AKBLF)ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.Read More AKBLF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKBLF Stock News HeadlinesMay 3, 2024 | finanznachrichten.deALK Abello: ALK upgrades its full-year revenue outlookMay 2, 2024 | finance.yahoo.comThree-month interim report (Q1) 2024 (unaudited)May 5, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...May 2, 2024 | markets.businessinsider.comAlk-Abello A-S Bearer and-or registered B is about to announce its earnings — here's what Wall Street expectsMay 2, 2024 | finance.yahoo.comALK upgrades its full-year revenue outlookApril 24, 2024 | finance.yahoo.comInvitation to the presentation of ALK’s first quarter results on Friday 3 May 2024April 18, 2024 | benzinga.comAlaska Air Gr Stock (NYSE:ALK), Quotes and News SummaryMarch 27, 2024 | finance.yahoo.comSave the date for ALK’s Capital Markets Day on 4 June 2024May 5, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...March 14, 2024 | finance.yahoo.comAnnual General Meeting in ALK-Abelló A/S held on 14 March 2024February 16, 2024 | finance.yahoo.comAnnual General Meeting in ALK-Abelló A/S on 14 March 2024February 8, 2024 | finanznachrichten.deALK Abello: Annual report 2023: ALK delivers 9% sales growth with profits up 50%February 8, 2024 | finanznachrichten.deALK Abello: ALK and McMaster researchers discover new cell that remembers allergiesFebruary 8, 2024 | finance.yahoo.comAnnual report 2023: ALK delivers 9% sales growth with profits up 50%February 7, 2024 | finance.yahoo.comALK and McMaster researchers discover new cell that remembers allergiesFebruary 5, 2024 | finance.yahoo.comALK’s 2030 CO2 reduction targets have been approved by SBTiJanuary 31, 2024 | finance.yahoo.comRelease date of annual report 2023 for ALK and webcastJanuary 25, 2024 | finance.yahoo.comALK’s European registration application for house dust mite SLIT-tablet in young children accepted for reviewJanuary 18, 2024 | finance.yahoo.comALK completes first part of phase 1 trial with peanut SLIT-tabletJanuary 4, 2024 | finanznachrichten.deALK Abello: ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergyJanuary 4, 2024 | finance.yahoo.comALK to Become Sole Manufacturer and Distributor of Skin Antigen Test for Penicillin AllergyDecember 21, 2023 | uk.investing.comALK-Abello B (0OIR)December 20, 2023 | finance.yahoo.comALK – Financial calendar for the 2024 financial yearDecember 12, 2023 | finanznachrichten.deALK Abello: ALK expands partnership with Torii in JapanDecember 12, 2023 | finance.yahoo.comALK expands partnership with Torii in JapanNovember 15, 2023 | finance.yahoo.comNine-month interim report (Q3) 2023November 9, 2023 | morningstar.comAlk-Abello A/S Class B ALK BSee More Headlines Receive AKBLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALK-Abelló A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTC SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTC:AKBLF CUSIPN/A CIKN/A Webwww.alk.net Phone45.45.74.75.76FaxN/AEmployees2,824Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Claus Steensen Solje (Age 52)Executive VP, CFO & Member of Management Board Comp: $2.03MMr. Søren Daniel Niegel (Age 53)Executive VP of Commercial Operations & Member of Management Board Comp: $766.2kDr. Henriette Mersebach (Age 53)Executive VP Research & Development & Member of Management Board Comp: $886.3kMs. Katja Barnkob Thalund (Age 55)Project Director of Global CMC Development & Employee-elected Director Comp: $50.34kMr. Peter Halling (Age 47)President & CEO Mr. Per PlotnikofVP of Corporate Communications, Investor Relations & Strategic Planning and Head of IRProf. Hendrik Kees Kam Nolte M.D.Ph.D., Senior Vice President of Research & Development - North America and International MarketsMr. Christian G. HoughtonHead of Product SupplyMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors AKBLF Stock Analysis - Frequently Asked Questions Should I buy or sell ALK-Abelló A/S stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ALK-Abelló A/S in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKBLF shares. View AKBLF analyst ratings or view top-rated stocks. How have AKBLF shares performed in 2024? ALK-Abelló A/S's stock was trading at $13.25 at the beginning of 2024. Since then, AKBLF stock has increased by 35.1% and is now trading at $17.90. View the best growth stocks for 2024 here. How do I buy shares of ALK-Abelló A/S? Shares of AKBLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTC:AKBLF) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCCharles Payne Demystifies OptionsUnstoppable ProsperityThe asset beating inflation by 4xColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALK-Abelló A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.